The Incidence of Extended-spectrum β-lactamase (ESBL) Klebsiella Pneumonia in Patient on Renal Replacement Therapy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Hoseok Koo, Inje University
ClinicalTrials.gov Identifier:
NCT01612182
First received: May 29, 2012
Last updated: June 4, 2012
Last verified: June 2012
  Purpose

The prevalence of ESBL Klebsiella pneumonia was higher in patient with renal replacement therapy.


Condition Intervention
End-stage Renal Disease
Other: renal replacement therapy

Study Type: Observational
Study Design: Time Perspective: Retrospective

Resource links provided by NLM:


Further study details as provided by Inje University:

Primary Outcome Measures:
  • The prevalence of ESBL Klebsiella pneumonia in renal replacement therapy [ Time Frame: During hospitalization ] [ Designated as safety issue: No ]
    The prevalence of ESBL Klebsiella pneumonia in renal replacement therapy during hospitalization up to 8 years (from 2004 to 2011)


Secondary Outcome Measures:
  • The prevalence of ESBL Klebsiella pneumonia in patient with pneumonia and renal replacement therapy [ Time Frame: during hospitalization ] [ Designated as safety issue: No ]
    The prevalence of ESBL Klebsiella pneumoina in patient with pneumonia and renal replacement therapy during hospitalization up to 8 years (from 2004 to 2011)


Enrollment: 1289
Study Start Date: March 2012
Study Completion Date: May 2012
Groups/Cohorts Assigned Interventions
ESBL(+) Klebsiella pneumonia
All the patient who's the culture result showed ESBL(+) Klebsiella pneumonia in any site during hospitalization
Other: renal replacement therapy
renal replacement therapy : hemodialysis and/or CRRT(continuous renal replacement therapy )
ESBL(-) Klebsiella pneumonia
All the patient who's the culture result showed ESBL(-) Klebsiella pneumonia in any site during hospitalization
Other: renal replacement therapy
renal replacement therapy : hemodialysis and/or CRRT(continuous renal replacement therapy )

  Eligibility

Ages Eligible for Study:   18 Years to 79 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

The patients had admitted in single center

Criteria

Inclusion Criteria:

  • The age of patient was between 18 yrs and 79 yrs.
  • The patient who showed Klebsiella pneumonia in 1st culture result of any site during hospitalization

Exclusion Criteria:

  • The level of serum albumin was below 2.0 or over 5.0
  • The level of AST or ALT was 2 times of normal level or the level of bilirubin was over 2.0 mg/dL during 1month.
  • The level of Body mass index was below 15 or over 30
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01612182

Locations
Korea, Republic of
Inje University Seoul Paik hospital Instituional Board Review
Seoul, Je dong 2ga, Jung gu, Korea, Republic of, 100-032
Sponsors and Collaborators
Inje University
  More Information

No publications provided

Responsible Party: Hoseok Koo, Nephrology division, Department of Internal Medicine, Inje University
ClinicalTrials.gov Identifier: NCT01612182     History of Changes
Other Study ID Numbers: ESBL 2012-1
Study First Received: May 29, 2012
Last Updated: June 4, 2012
Health Authority: Korea: Food and Drug Administration

Keywords provided by Inje University:
end-stage renal disease
renal replacement therapy

Additional relevant MeSH terms:
Kidney Diseases
Kidney Failure, Chronic
Urologic Diseases
Renal Insufficiency, Chronic
Renal Insufficiency

ClinicalTrials.gov processed this record on August 19, 2014